Published in Arch Neurol on February 01, 1993
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry (2005) 2.54
Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol (2009) 2.29
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology (2014) 2.15
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain (2012) 1.99
Brain amyloid and cognition in Lewy body diseases. Mov Disord (2012) 1.87
Parkinson's disease. J Neurol Neurosurg Psychiatry (1994) 1.84
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (1998) 1.75
Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol (1999) 1.60
Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry (2003) 1.56
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One (2013) 1.54
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol (2011) 1.45
Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol (2010) 1.41
Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry (1997) 1.38
Epidemiology of Parkinson's disease. J Neurol (2008) 1.38
Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage (2010) 1.36
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology (2012) 1.33
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol (2013) 1.32
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J Clin Neurol (2011) 1.21
Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol (2008) 1.18
Neuroimaging and therapeutics in movement disorders. NeuroRx (2005) 1.17
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry (2002) 1.16
Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis (2009) 1.15
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2012) 1.15
What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry (2000) 1.14
Approach to diagnosis of Parkinson disease. Can Fam Physician (2006) 1.13
The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun (2013) 1.11
Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging (2008) 1.08
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord (2013) 1.07
Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol (2007) 1.05
Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism Relat Disord (2013) 1.02
Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.01
Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 0.98
Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord (2009) 0.97
Vascular parkinsonism--characteristics, pathogenesis and treatment. Nat Rev Neurol (2015) 0.97
Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry (1998) 0.96
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Amyloid polymorphism: structural basis and neurobiological relevance. Neuron (2015) 0.95
Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem (2009) 0.95
Impaired financial abilities in Parkinson's disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord (2013) 0.93
Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease. J Neurol Neurosurg Psychiatry (1996) 0.92
Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. J Zhejiang Univ Sci B (2011) 0.91
Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci (2004) 0.90
Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis (2012) 0.89
Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol (2014) 0.89
The neuropsychiatric profile of Parkinson's disease subjects with and without mild cognitive impairment. J Neural Transm (Vienna) (2013) 0.88
Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging (2005) 0.88
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 0.88
Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol (2012) 0.87
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord (2015) 0.87
Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. PLoS One (2015) 0.86
Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord (2012) 0.86
Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol (2010) 0.86
Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial. Trials (2009) 0.86
Digitized Spiral Drawing: A Possible Biomarker for Early Parkinson's Disease. PLoS One (2016) 0.85
Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history. Neurogenetics (2007) 0.84
Cognitive impairment in Parkinson's disease without dementia: subtypes and influences of age. J Clin Neurol (2009) 0.84
Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.84
Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. Am J Neurodegener Dis (2012) 0.83
Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther (2014) 0.82
The human gastrointestinal tract, a potential autologous neural stem cell source. PLoS One (2013) 0.82
Different diagnostic criteria for Parkinson disease: what are the pitfalls? J Neural Transm (Vienna) (2013) 0.82
Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis (2012) 0.82
Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunction. Front Aging Neurosci (2014) 0.82
Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis. Sci Rep (2016) 0.81
An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. PLoS One (2016) 0.81
Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn) (2016) 0.80
Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. J Neural Transm (Vienna) (2005) 0.80
PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. Neurodegener Dis (2015) 0.80
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol (2016) 0.79
Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry (2004) 0.79
Nonmotor symptoms in early- and advanced-stage Parkinson's disease patients on dopaminergic therapy: how do they correlate with quality of life? ISRN Neurol (2014) 0.79
Electrocorticography reveals beta desynchronization in the basal ganglia-cortical loop during rest tremor in Parkinson's disease. Neurobiol Dis (2015) 0.79
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol (2016) 0.79
Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements. Sci Rep (2016) 0.79
Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease. US Neurol (2011) 0.78
Assessment of Nonverbal and Verbal Apraxia in Patients with Parkinson's Disease. Parkinsons Dis (2015) 0.78
In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms. Clin Auton Res (2015) 0.77
Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord (2014) 0.77
Driving errors in Parkinson's disease: moving closer to predicting on-road outcomes. Am J Occup Ther (2013) 0.77
Screening for impaired cognitive domains in a large Parkinson's disease population and its application to the diagnostic procedure for Parkinson's disease dementia. Dement Geriatr Cogn Dis Extra (2014) 0.77
Mild cognitive impairment exists in Parkinson's disease. J Neural Transm (Vienna) (2011) 0.77
Contribution of inter-muscular synchronization in the modulation of tremor intensity in Parkinson's disease. J Neuroeng Rehabil (2015) 0.76
Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. Brain Behav (2016) 0.76
Correlative (99m)tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease. World J Nucl Med (2014) 0.76
The benefits of pramipexole selection in the treatment of Parkinson's disease. Neurol Sci (2014) 0.76
Nanoparticle transport across the blood brain barrier. Tissue Barriers (2016) 0.76
Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurol Genet (2016) 0.76
Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. Parkinsons Dis (2016) 0.75
The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes. J Neurol (2015) 0.75
Parkinsonism and tremor disorders. A clinical approach. Libyan J Med (2007) 0.75
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord (2016) 0.75
Temporal fluctuations of tremor signals from inertial sensor: a preliminary study in differentiating Parkinson's disease from essential tremor. Biomed Eng Online (2015) 0.75
Syndromic approach to Parkinson's disease: role of functional imaging. J Clin Neurol (2006) 0.75
Rest tremor revisited: Parkinson's disease and other disorders. Transl Neurodegener (2017) 0.75
Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies. Parkinsons Dis (2012) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Mov Disord (2011) 6.45
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry (2000) 3.89
Striatonigral degeneration. A clinicopathological study. Brain (1990) 3.70
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 3.53
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry (1991) 3.38
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
The impact of treatment with levodopa on Parkinson's disease. Q J Med (1980) 3.14
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology (2011) 3.10
Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet (1988) 2.80
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain (1994) 2.77
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Cognitive deficits in the early stages of Parkinson's disease. Brain (1983) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord (1997) 2.61
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 2.42
The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology (1997) 2.36
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet (1990) 2.30
Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl (1993) 2.27
Spinal internuncial neurones in progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1979) 2.20
Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology (2000) 2.19
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord (1998) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Low-dose olanzapine for levodopa induced dyskinesias. Neurology (2000) 2.03
The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol (2012) 2.03
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry (1989) 1.95
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology (2001) 1.87
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 1.83
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83
The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol (1989) 1.79
Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol (1995) 1.79
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology (2005) 1.77
Acute movement disorders with bilateral basal ganglia lesions in uremia. Mov Disord (1998) 1.74
A clinical study of Gilles de la Tourette syndrome in the United Kingdom. J Neurol Neurosurg Psychiatry (1984) 1.72
Neurological deterioration in young adults with phenylketonuria. Lancet (1990) 1.71
Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry (1991) 1.69
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem (1990) 1.66
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology (2003) 1.61
New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology (1991) 1.57
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57
Tau gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry (2004) 1.56
The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1986) 1.55
Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 1.54
Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience (2005) 1.51
Cerebral tuberculomas developing during treatment of tuberculous meningitis. Lancet (1980) 1.51
Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry (2003) 1.51
Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1990) 1.50
Incidental Lewy body disease in black Africans. Lancet (1994) 1.50
Alpha-tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol (1992) 1.49
Chronic basal meningitis and vasculitis in acquired immunodeficiency syndrome. A possible role for human immunodeficiency virus. Arch Pathol Lab Med (1989) 1.49
Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A (2000) 1.48
Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.48
Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology (1999) 1.46
Granular cell tumours of the orbit. Aust N Z J Ophthalmol (1991) 1.45
The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain (2001) 1.44
Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain (1987) 1.44
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry (2004) 1.44
Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain (1987) 1.44
Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol (1992) 1.43
Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. Mov Disord (1995) 1.43
Parkinsonism following electrical injury to the hand. Mov Disord (1998) 1.42
Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report. Mov Disord (1991) 1.42
Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain (1992) 1.40
Transplantation in Parkinson's disease. Br J Hosp Med (1989) 1.39
The psychopathology of the Gilles de la Tourette syndrome. A phenomenological analysis. Br J Psychiatry (1988) 1.39
Increased nigral iron content in postmortem parkinsonian brain. Lancet (1987) 1.39
Sign language tics in a prelingually deaf man. Mov Disord (2000) 1.38
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol (1994) 1.36
Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology (2003) 1.35